Although a TITR over 50% can be considered a reasonable and safe goal for treatment targets in individuals living with T1D, Castañeda et al. showed that a goal exceeding 55% could be reasonably achieved in MM780G AHCL system users if optimal system settings are applied (target 100 mg/dL, insulin duration 2 h). The gene discussed is INS; the disease is type 1 diabetes mellitus.